| Co-Investigator(Kenkyū-buntansha) |
HOSONO Osamu 東京大学, 医科学研究所, 助教 (50190210)
IWATA Satoshi 東京大学, 医科学研究所, 特任講師 (00396871)
YAMOCHI Tadanori 東京大学, 医科学研究所, 産学官連携研究員 (80306844)
KAWASAKI Hiroshi 東京大学, 医科学研究所, 助教 (80280957)
OHNUMA Kei 東京大学, 医科学研究所, 助教 (10396872)
IKEDA Teturo 東京大学, 医科学研究所, 特任研究員 (10360489)
|
|---|
| Budget Amount *help |
¥112,060,000 (Direct Cost: ¥86,200,000、Indirect Cost: ¥25,860,000)
Fiscal Year 2009: ¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2008: ¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2007: ¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2006: ¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2005: ¥37,180,000 (Direct Cost: ¥28,600,000、Indirect Cost: ¥8,580,000)
|
|---|
| Research Abstract |
We have identified caveolin-1 as the costimulatory ligand for CD26. The 82-101th amino acid (a・a) of caveolin-1 bound to the 201-211th a・a of CD26 with the DPPIV catalytic site of 630^<th> a・a, Serine. Moreover, we found that cytoplasmic tail of CD26 interacts with CARMA-1 in T cells, resulting in the induction of costimulatory signal. After injection of human PBL into SCID mice, the symptom of xeno-GVHD has been induced and human T cells play a role in pathophysiology of x-GVHD as effectors. Treatment of these x-GVHD mice with humanized CD26 antibody resulted in improvement of the symptom of x-GVHD, suggesting that anti-CD26 treatment leads to the effective treatment of human immune-mediated diseases such as autoimmune disorders and GVHD after allo-BMT.
|
